Three major regions are moving in parallel to create dedicated AI governance systems for medicine, each tailored to their regulatory landscape and healthcare priorities. Australia is developing its first integrated legal framework for AI-enhanced gene editing, China has launched a six-month pilot program to standardize AI ethics reviews across cities, and Brazil has published sector-specific standards for responsible AI use in medical practice. Together, these initiatives reveal a global pattern: healthcare regulators are no longer waiting for broad AI legislation to catch up with clinical reality.

Why Is Healthcare Becoming the Test Ground for AI Regulation?

Healthcare sits at the intersection of three urgent pressures: rapid AI adoption, sensitive personal data, and life-or-death consequences. In Australia, patients are already receiving AI-enhanced gene therapies like Casgevy through clinical trials and approved products, yet the country's existing laws were written separately and don't address how these hybrid technologies should be evaluated or governed. The Gene Technology Act 2000, the Therapeutic Goods Act 1989, and the Privacy Act 1988 each contain relevant rules, but they leave critical gaps when AI is used to interpret genomic data or design CRISPR therapies.

Brazil's Federal Council of Medicine, the national body regulating medical ethics, recognized this gap and published Resolution No. 2,454/2026 in June 2026. The resolution establishes standards for research, development, governance, auditing, monitoring, training, and responsible use of AI models, systems, and applications in medicine. Even though it is not a general law, the resolution operates as a sector-specific standard of care for AI in medicine, influencing internal policies, care pathways, and supplier contracts across Brazilian healthcare.

What Does a Practical AI Governance System Look Like?

China's approach offers a window into how governance can be operationalized at scale. On May 9, 2026, the Ministry of Industry and Information Technology issued a notice launching a pilot scheme for AI science and technology ethics reviews and services. The pilot, running from June 1 to November 30, 2026, explores best practices and refines mechanisms to build a comprehensive AI ethics review system linking central, provincial, and municipal efforts through multi-stakeholder collaboration.

The pilot's structure reveals how regulators are thinking about AI governance in practice:

• Local Governance Frameworks: Participating cities refine provincial review regulations and establish municipal coordination mechanisms across departments to ensure consistent oversight.
• Ethics Committees and Review Centers: Professional institutions provide independent oversight and professional services for organizations lacking internal ethics capacity.
• Standardization as a Core Pillar: Cities conduct practical ethics assessments using existing guidelines for AI ethics risk assessment and generative AI ethics as reference standards, with the goal of converting proven practices into formal technical standards.
• Three-Tier Agile Governance Network: The system enables information sharing, risk reporting, and early warning capabilities across local, provincial, and central levels.

For high-risk AI activities, provincial authorities will establish expert review protocols and conduct at least three expert reviews during the pilot period. These insights feed into dynamic updates of the high-risk activity list, ensuring governance evolves with the technology.

How Are Different Regions Balancing Innovation and Safety?

Australia's approach emphasizes life-cycle governance. Brazil's Resolution No. 2,454/2026 adopts a similar philosophy, providing that verifications and controls accompany AI systems from conception and testing through implementation, updates, retraining, and monitoring in production. This contrasts with earlier regulatory models that focused on approval gates; instead, these frameworks treat AI governance as an ongoing responsibility.

The Australian Centre for Health Law Research is building the country's first integrated legal and ethical analysis of AI-enhanced gene editing. The project compares Australian regulation with EU and US approaches to inform reform and safeguard patient safety. A policy brief for Australian regulators, including the Office of the Gene Technology Regulator, the Therapeutic Goods Administration, and the Office of the Australian Information Commissioner, will translate comparative analysis into actionable recommendations for reforming the Gene Technology Act 2000 and TGA approval pathways.

Without an integrated framework, Australia risks either over-restricting beneficial innovation or under-protecting patients. The research team noted that faster, safer access to therapies such as Casgevy and its successors depends on clearer privacy and consent guidance for the genomic data of all patients whose tissue is sequenced in AI-enabled workflows.

What Are the Immediate Practical Implications for Healthcare Organizations?

Brazil's resolution has concrete implications for how healthcare organizations operate. Even though it is not a general law, CFM resolutions serve as normative references for medical practice and the organization of services under medical technical direction, with concrete implications for supervision and ethical-professional oversight. This means the resolution will influence internal policies, the design of care pathways, and increasingly, criteria for contracting, validating, and monitoring suppliers.

China's pilot program offers recognition and preferential policy and funding support to high-performing regions upon completion. This incentive structure suggests that regulators view AI governance not as a compliance burden but as a competitive advantage for regions that can demonstrate responsible innovation.

The convergence of these three initiatives signals that healthcare is becoming the template for sector-specific AI governance globally. Rather than waiting for broad AI legislation, regulators are building tailored frameworks that address the unique risks and opportunities of their industries. As these pilots mature and produce results, other sectors and regions will likely follow the healthcare model, creating a patchwork of specialized AI governance systems rather than a single global rulebook.